Showing results (81-90 of 95) with videos related to
Sort By:
Pageof 10
Plos One|June 6, 2017
A phase I study of single-agent perifosine for recurrent or refractory pediatric CNS and solid tumorsOren J Becher, Nathan E Millard, Shakeel Modak, et al.Oncotarget|June 11, 2015
Orthogonal targeting of EGFRvIII expressing glioblastomas through simultaneous EGFR and PLK1 inhibitionYing Shen, Jie Li, Masayuki Nitta, et al.Plos One|December 22, 2025
Effects of combination therapy of a CDK4/6 and MEK inhibitor in diffuse midline glioma preclinical modelsYusuke Tomita, Gabrielle Link, Yi Ge, et al.The Lancet. Child & Adolescent Health|April 2, 2023
Recombinant polio-rhinovirus immunotherapy for recurrent paediatric high-grade glioma: a phase 1b trialEric M Thompson, Daniel Landi, Michael C Brown, et al.Oncoimmunology|October 3, 2022
Immunotherapy approaches for the treatment of diffuse midline gliomasJoshua D Bernstock, Samantha E Hoffman, Ari D Kappel, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 23, 2019
Radiosensitization by Histone H3 Demethylase Inhibition in Diffuse Intrinsic Pontine GliomaHiroaki Katagi, Nundia Louis, Dusten Unruh, et al.Biorxiv : the Preprint Server for Biology|October 31, 2023
<i>Ataxia-telangiectasia mutated</i> ( <i>Atm</i> ) disruption sensitizes spatially-directed H3.3K27M/TP53 diffuse midline gliomas to radiation therapyAvani Mangoli, Sophie Wu, Harrison Q Liu, et al.Cancer Research|June 16, 2019
Identification of Novel RAS Signaling Therapeutic Vulnerabilities in Diffuse Intrinsic Pontine GliomasRobert F Koncar, Brittany R Dey, Ann-Catherine J Stanton, et al.Neuro-Oncology|June 11, 2016
Pediatric high-grade glioma: biologically and clinically in need of new thinkingChris Jones, Matthias A Karajannis, David T W Jones, et al.Cell Reports. Medicine|June 27, 2025
Targeting the CD40 costimulatory receptor to improve virotherapy efficacy in diffuse midline gliomasSara Labiano, Javier Marco-Sanz, Iker Ausejo-Mauleon, et al.Pageof 10